FDA’s New Draft Guidance on Non-Opioid Analgesics: A Needed Shift in Chronic Pain Treatment

Blogs

Written by Lynn Webster, MD, Executive Vice President, Scientific Affairs, Dr. Vince Clinical Research

Last week, the FDA released draft guidance to accelerate the development of non-opioid treatments for chronic pain. This is not just a regulatory update—it reflects a broader public health commitment to expand safe and effective options for millions of Americans living with persistent pain.

Earlier guidance (2019) largely emphasized condition-specific approvals and placebo-controlled trials. While important, that approach often limited innovation and slowed progress. The new 2025 draft guidance introduces a more flexible, mechanism-based framework. It allows developers to pursue broader indications (from condition-specific to group-specific or even general chronic pain) when there is scientific evidence of shared pain pathways. This means potentially fewer duplicative trials and faster access to therapies.

The FDA also encourages innovative trial designs—including adaptive methods, pragmatic and decentralized studies, and the use of biomarkers and digital health technologies. Importantly, it sets a clearer standard for demonstrating opioid reduction benefits: whether a new therapy can help patients avoid, eliminate, or reduce opioid use while maintaining pain control.

The rationale is clear: opioids remain a necessary option for some, but their risks underscore the urgency of expanding alternatives. By emphasizing patient-reported outcomes, functional measures like sleep and daily activity, and diversity in trial populations, the guidance reflects a modern, patient-centered approach.

In short, this guidance is a welcome step toward balancing innovation with rigor. It creates pathways for therapies that are not only effective, but that can also reduce reliance on opioids—offering hope for patients, families, and clinicians navigating the complex reality of chronic pain.

Lynn Webster, MD

Lynn Webster, MD

Lynn Webster, MD, Executive Vice President of Scientific Affairs, is an internationally recognized clinical research expert in pain and addiction medicine. He has participated as an Investigator in hundreds of clinical trials and has authored more than 300 peer reviewed articles. He is board certified in anesthesiology, pain medicine and addiction medicine. He is the former co-founder of Lifetree Medical as well as an editor of Pain Medicine. Dr. Webster also serves as a peer reviewer of several professional journals and is a National Institute of Health grant reviewer. He has significant expertise in clinical research with a focus in experimental and human pain models, human abuse potential studies as well as assessing drugs’ effects on respiratory depression.

Center for Drug Evaluation and Research. Development of non-opioid analgesics for chronic pain [Internet]. FDA; 2025 [cited 2025 Sept 18]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-non-opioid-analgesics-chronic-pain

Center for Drug Evaluation and Research. Opioid analgesic drugs: Considerations for benefit-risk assessment FRA [Internet]. FDA; 2019 [cited 2025 Sept 19]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/opioid-analgesic-drugs-considerations-benefit-risk-assessment-framework-guidance-industry